G
Gary M. Marsh
Researcher at University of Pittsburgh
Publications - 202
Citations - 6633
Gary M. Marsh is an academic researcher from University of Pittsburgh. The author has contributed to research in topics: Cohort & Cohort study. The author has an hindex of 38, co-authored 199 publications receiving 6256 citations. Previous affiliations of Gary M. Marsh include Virginia Tech & University of Illinois at Chicago.
Papers
More filters
Journal ArticleDOI
Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type.
TL;DR: It is suggested that THA may be at least temporarily useful in the long-term palliative treatment of patients with Alzheimer's disease, and further observations will be required before a clear assessment of the role of this agent can be made.
Journal ArticleDOI
Aspartame: A Safety Evaluation Based on Current Use Levels, Regulations, and Toxicological and Epidemiological Studies
B. A. Magnuson,G. A. Burdock,John Doull,Rob Kroes,Gary M. Marsh,M. W. Pariza,Peter S. Spencer,William J. Waddell,R. Walker,Gary M. Williams +9 more
TL;DR: The data from the extensive investigations into the possibility of neurotoxic effects of aspartame, in general, do not support the hypothesis that aspartam in the human diet will affect nervous system function, learning or behavior.
Journal ArticleDOI
Population attributable risk of aflatoxin-related liver cancer: systematic review and meta-analysis.
TL;DR: In high exposure areas, aflatoxin multiplicatively interacts with HBV to induce HCC; reducing aflat toxin exposure to non-detectable levels could reduce HCC cases in high-risk areas by about 23%.
Journal Article
Use of THA in treatment of Alzheimer-like dementia: pilot study in twelve patients.
TL;DR: THA, a centrally acting anticholinesterase was given intravenously in varying doses to 12 unselected cases of Alzheimer-like senile dementia and significant improvement in memory testing occurred in 6 of 12 subjects; 9 of 12 improved in clinical staging.
Journal ArticleDOI
Comparative incidence of de novo nonlymphoid malignancies after liver transplantation under tacrolimus using surveillance epidemiologic end result data.
Ashokkumar Jain,LD Yee,M. A. Nalesnik,Ada O. Youk,Gary M. Marsh,Jorge Reyes,Marsha Zak,Jorge Rakela,William Irish,J. J. Fung +9 more
TL;DR: An increased incidence of de novo cancers in the chronically immunocompromised patient demands careful long-term screening protocols which will help to facilitate the diagnosis at an early stage of the disease.